Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AACR 2022 | KEYNOTE-B84: pepinemab + pembrolizumab for metastatic/recurrent head & neck squamous cell carcinoma

Terrence L. Fisher • 12 Apr 2022
AACR 2022
Head and Neck Cancer Skin Cancer Antibodies Pembrolizumab Pepinemab
KEYNOTE-B84

Terrence L. Fisher, PhD, Vaccinex Inc., Rochester, NY, discusses the Phase I/II KEYNOTE-B84 trial (NCT04815720) of pepinemab plus pembrolizumab as a first-line treatment in patients with metastatic or recurrent head and neck squamous cell carcinoma. Data from the safety run-in stage was presented at AACR 2022, including the recommended Phase II dosage. This interview took place at the American Association for Cancer Research Annual Meeting 2022 in New Orleans, LA.

More from Terrence L. Fisher

1:03
Mechanism of action of the novel SEMA4D inhibitor, pepinemab
Terrence L. Fisher • 12 Apr 2022
0:39
Applications of pepinemab in oncology and neurology
Terrence L. Fisher • 12 Apr 2022

Related Videos

1:27
Emerging trials in melanoma: SWOG S1801, OpACIN-neo and PRADO
Christoffer Gebhardt • 9 Apr 2024
2:12
Novel immunotherapeutic approaches to treat patients with melanoma
Christoffer Gebhardt • 9 Apr 2024
1:22
INTerpath-001: individualized neoantigen vaccines with pembrolizumab in melanoma
Christoffer Gebhardt • 9 Apr 2024
2:15
Reducing the need for sentinel node biopsies in cutaneous melanoma
Christoffer Gebhardt • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals